Clinical Trial Update: Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of LY3023414 for recurrent or persistent endometrial cancer has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• LY3023414 (samotolisib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Endometrial Cancer, Recurrent Endometrial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-02-22